Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC-A Brief Report From the CROWN Study.

ABSTRACT:

Introduction

Lorlatinib was found to have improved efficacy versus crizotinib in the global phase 3 CROWN study (NCT03052608). Similar results were revealed for the Japanese population as for the overall population. We present results from the unplanned 3-year follow-up from the CROWN study in Japanese patients.

Methods

Patients were randomized to either lorlatinib 100 mg once daily (n = 25) or crizotinib 250 mg twice daily (n = 23). The primary end point was progression-free survival assessed by blinded independent central review. Secondary end points included objective and intracranial responses assessed by blinded independent central review and safety.

Results

At the data cutoff of September 20, 2021, median progression-free survival was not reached with lorlatinib

SUBMITTER: Teraoka S 

PROVIDER: S-EPMC10906525 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature